



Takeda launches CINRYZE for treatment of hereditary angioedema patients in India

14 December 2022 | News

CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE

Takeda Biopharmaceuticals India (formerly known as Baxalta Bioscience India), has launched CINRYZE, an innovative injectable prescription medicine for the treatment of hereditary angioedema (HAE) patients.

With eight years of global clinical experience proving efficacy and safety, CINRYZE has the potential to mark a breakthrough in the episodic treatment, short and long-term prophylaxis for HAE. Moreover, CINRYZE is the pioneer C1 esterase inhibitor (C1-I NH) approved by the FDA & EMA for the symptomatic management of HAE and for preventing future angioedema attacks.

CINRYZE is indicated in India for routine prevention (prophylaxis) of angioedema attacks in adults, adolescents and children 6 years of age and above with HAE; and treatment of angioedema attacks and pre-procedure prevention of angioedema attacks in adults, adolescents and children 2 years of age and above with HAE.

Hereditary Angioedema (HAE) is a rare genetic condition that causes swelling in different parts of the body like limbs, face, abdomen, and larynx. HAE is caused by a mutation in the gene which produce protein called the C1 esterase inhibitor leading to its reduced level or compromised functioning. Symptoms of HAE often present in childhood, and while attacks can occur at any age, early onset may predict a more severe disease course.